Component

C. zeylanicum extract in the 2025 diabetes trial

C. zeylanicum extract in the 2025 diabetes trial. Species, exposure and limitations are retained in each linked claim.

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. The extract groups showed reduced fasting plasma glucose from baseline; treatment assignment was a significant predictor of change in the reported regression.

    C. zeylanicum extract in the 2025 diabetes trial → Plasma glucose concentration source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/ceylon-research/41412108.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "41424e14da4786345bad52af19c8ccee1a37f445a402edaa855b87ee01d389b9", "start_char": 0, "end_char": 1887, "text_sha256": "41424e14da4786345bad52af19c8ccee1a37f445a402edaa855b87ee01d389b9"}
    experimental_model
    Three-arm randomized placebo-controlled diabetes trial
    exposure
    210 randomized; 186 completed four months; 250 or 500 mg extract groups
    limitations
    The accessible abstract reports within-baseline changes and regression significance, without a full numeric between-group effect estimate. Do not turn these into a precise placebo-adjusted magnitude.
    nutrient_topic
    Ceylon cinnamon research collection; topical membership is not evidence of a direct dietary effect. · Ceylon cinnamon / Cinnamomum verum bark preparations
    organism
    Human
    plain_language
    The study reported improved fasting plasma glucose, but the accessible abstract does not provide the full treatment-versus-placebo effect size.
    primary_references
    [ceylon-p41412108] Efficacy and Safety of Cinnamomum zeylanicum (Ceylon cinnamon) for diabetes mellitus: a randomized, double blind, placebo-controlled clinical trial. (2025). https://pubmed.ncbi.nlm.nih.gov/41412108/ DOI: 10.1016/j.dsx.2025.103357
    tissue_or_cell_type
    Type 2 diabetes cohort

    Ceylon cinnamon: metabolism, signaling and nutrient connections (2026-09-17) · lines 1169–1180

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Three-arm randomized placebo-controlled diabetes trial · source_derived_draft · unverified_draft

    ### ceylon-diabetes-fpg The extract groups showed reduced fasting plasma glucose from baseline; treatment assignment was a significant predictor of change in the reported regression. Condition category: normal nutrient_topic: Ceylon cinnamon research collection; topical membership is not evidence of a direct dietary effect. plain_language: The study reported improved fasting plasma glucose, but the accessible abstract does not provide the full treatment-versus-placebo effect size. organism: Human tissue_or_cell_type: Type 2 diabetes cohort experimental_model: Three-arm randomized placebo-controlled diabetes trial limitations: The accessible abstract reports within-baseline changes and regression significance, without a full numeric between-group effect estimate. Do not turn these into a precise placebo-adjusted magnitude. exposure: 210 randomized; 186 completed four months; 250 or 500 mg extract groups evidence_span: {"source_cache": "artifacts/ceylon-research/41412108.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "41424e14da4786345bad52af19c8ccee1a37f445a402edaa855b87ee01d389b9", "start_char": 0, "end_char": 1887, "text_sha256": "41424e14da4786345bad52af19c8ccee1a37f445a402edaa855b87ee01d389b9"} [ceylon-p41412108] Efficacy and Safety of Cinnamomum zeylanicum (Ceylon cinnamon) for diabetes mellitus: a randomized, double blind, placebo-controlled clinical trial. (2025). https://pubmed.ncbi.nlm.nih.gov/41412108/ DOI: 10.1016/j.dsx.2025.103357
    Complete structured claim and evidence

  2. The extract groups showed reduced HbA1c from baseline; treatment assignment was a significant predictor of change in the reported regression.

    C. zeylanicum extract in the 2025 diabetes trial → Glycated hemoglobin / HbA1c concentration source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/ceylon-research/41412108.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "41424e14da4786345bad52af19c8ccee1a37f445a402edaa855b87ee01d389b9", "start_char": 0, "end_char": 1887, "text_sha256": "41424e14da4786345bad52af19c8ccee1a37f445a402edaa855b87ee01d389b9"}
    experimental_model
    Three-arm randomized placebo-controlled diabetes trial
    exposure
    210 randomized; 186 completed four months; 250 or 500 mg extract groups
    limitations
    The accessible abstract reports within-baseline changes and regression significance, without a full numeric between-group effect estimate. Do not turn these into a precise placebo-adjusted magnitude.
    nutrient_topic
    Ceylon cinnamon research collection; topical membership is not evidence of a direct dietary effect. · Ceylon cinnamon / Cinnamomum verum bark preparations
    organism
    Human
    plain_language
    The study reported improved HbA1c, but the accessible abstract does not provide the full treatment-versus-placebo effect size.
    primary_references
    [ceylon-p41412108] Efficacy and Safety of Cinnamomum zeylanicum (Ceylon cinnamon) for diabetes mellitus: a randomized, double blind, placebo-controlled clinical trial. (2025). https://pubmed.ncbi.nlm.nih.gov/41412108/ DOI: 10.1016/j.dsx.2025.103357
    tissue_or_cell_type
    Type 2 diabetes cohort

    Ceylon cinnamon: metabolism, signaling and nutrient connections (2026-09-17) · lines 1182–1193

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Three-arm randomized placebo-controlled diabetes trial · source_derived_draft · unverified_draft

    ### ceylon-diabetes-hba1c The extract groups showed reduced HbA1c from baseline; treatment assignment was a significant predictor of change in the reported regression. Condition category: normal nutrient_topic: Ceylon cinnamon research collection; topical membership is not evidence of a direct dietary effect. plain_language: The study reported improved HbA1c, but the accessible abstract does not provide the full treatment-versus-placebo effect size. organism: Human tissue_or_cell_type: Type 2 diabetes cohort experimental_model: Three-arm randomized placebo-controlled diabetes trial limitations: The accessible abstract reports within-baseline changes and regression significance, without a full numeric between-group effect estimate. Do not turn these into a precise placebo-adjusted magnitude. exposure: 210 randomized; 186 completed four months; 250 or 500 mg extract groups evidence_span: {"source_cache": "artifacts/ceylon-research/41412108.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "41424e14da4786345bad52af19c8ccee1a37f445a402edaa855b87ee01d389b9", "start_char": 0, "end_char": 1887, "text_sha256": "41424e14da4786345bad52af19c8ccee1a37f445a402edaa855b87ee01d389b9"} [ceylon-p41412108] Efficacy and Safety of Cinnamomum zeylanicum (Ceylon cinnamon) for diabetes mellitus: a randomized, double blind, placebo-controlled clinical trial. (2025). https://pubmed.ncbi.nlm.nih.gov/41412108/ DOI: 10.1016/j.dsx.2025.103357
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards